secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2023-09-29T23:59:59+00:00
Accession:  0001104659-23-105027
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics GSBR-1290 Phase 1b shows 4.9% weight loss but Phase 2a obesity data delayed to H1 2024
--------------------------------------------------------------------------------

- Phase 1b MAD: placebo-adjusted weight loss up to 4.9% at day 28; no severe AEs or discontinuations.
- Phase 2a obesity cohort data collection omission: 24 of 40 patients missing week 12 weight; new enrollment; topline now H1 2024.
- Phase 2a type 2 diabetes cohort topline still on track for latter half Q4 2023.
- Phase 2b studies (T2D ~500 pts, obesity ~275 pts) planned for 2024; formulation bridging study to tablets underway.
- GSBR-1290 generally well-tolerated; most AEs mild GI events; no clinically meaningful liver function changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923105027/0001104659-23-105027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923105027/tm2327162d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-105027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer